BioPharmSignal logoBioPharmSignal

Biotech News

SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025

SELLAS Life Sciences Group, Inc. (SLS)SELLAS Life Sciences Group, Inc.Clinical readout

SLS (SLS) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is sls.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

SLSSELLAS Life Sciences Group, Inc.2026-09-25 17:00 EST

SELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic Cancer

WVEWave Life Sciences2026-09-23 11:30 EST

Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity

SLSSELLAS Life Sciences Group, Inc.2026-09-02 12:30 EST

SELLAS Life Sciences to Present Preclinical Data on SLS009 in Pancreatic Ductal Adenocarcinoma at the 2026 AACR Conference on Pancreatic Cancer

CGEMCullinan Therapeutics, Inc.2026-10-08 11:00 EST

Cullinan Therapeutics Announces First Patient Dosed in Planned Registrational Phase 2 Study of CLN-049 in Relapsed/Refractory Acute Myeloid Leukemia

BMYBMYBristol-Myers Squibb Company2026-09-08 10:59 EST

Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ...

GSKGSK plc2026-09-13 19:30 EST

GSK presents positive registrational data to potentially expand Jideytro (zidesamtinib) to first-line ROS1-positive non-small cell lung cancer

ARGXArgenx2026-10-08 05:00 EST

argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease

TEVATeva Pharmaceutical Industries2026-09-02 11:03 EST

Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential

ARGXArgenx2026-08-17 05:00 EST

argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis

IDYAIDEAYA Biosciences2026-09-09 10:00 EST

IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma

View all latest news

SELLAS Life Sciences Group, Inc.

Late-Stage Oncology Company SELLAS Life Sciences develops therapies for hematologic malignancies and solid tumors. Its pipeline combines a WT1-targeted immunotherapy with a differentiated small-molecule CDK9 inhibitor. Galinpepimut-S Galinpepimut-S, or GPS, is a WT1-targeting immunotherapy licensed from Memorial Sloan Kettering Cancer...

Recent company news

SLSSELLAS Life Sciences Group, Inc.2026-09-25 17:00 EST

SELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic Cancer

SLSSELLAS Life Sciences Group, Inc.2026-09-02 12:30 EST

SELLAS Life Sciences to Present Preclinical Data on SLS009 in Pancreatic Ductal Adenocarcinoma at the 2026 AACR Conference on Pancreatic Cancer

SLSSELLAS Life Sciences Group, Inc.2026-08-11 20:05 EST

SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

SLSSELLAS Life Sciences Group, Inc.2026-05-14 12:00 EST

SELLAS Life Sciences to Participate in Upcoming Investor Conferences

SLSSELLAS Life Sciences Group, Inc.2026-05-12 20:05 EST

SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update

Stock data

Close
11.34 USD
Market cap
1.55B USD
Exchange
NASDAQ
Sector
Life Science Tools
Location
United States